# Adicet Bio, Inc.: financial statements, quarterly

ACET · Nasdaq · CIK 1720580 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 26

Pages: [Overview](/companies/acet.md) · [Financials](/companies/acet/financials.md) · [Filings](/companies/acet/filings.md) · [Insiders](/companies/acet/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/acet/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [26.2](/filings/0000950170-24-122253.md) | [24.8 d](/filings/0000950170-25-034587.md) | [23.9](/filings/0000950170-25-064448.md) | [25.9](/filings/0000950170-25-104978.md) | [26.3](/filings/0001193125-25-266880.md) | [23.3 d](/filings/0001720580-26-000008.md) | [22.8](/filings/0001720580-26-000037.md) | [28.4](/filings/0001720580-26-000050.md) | [22.9](/filings/0001193125-25-266880.md) | [25.0 d](/filings/0001720580-26-000008.md) | [17.5](/filings/0001720580-26-000037.md) | [18.5](/filings/0001720580-26-000050.md) |
| Operating income | $m | [(52.3)](/filings/0000950170-24-122253.md) | [(31.6) d](/filings/0000950170-25-034587.md) | [(30.9)](/filings/0000950170-25-064448.md) | [(32.8)](/filings/0000950170-25-104978.md) | [(33.2)](/filings/0001193125-25-266880.md) | [(30.7) d](/filings/0001720580-26-000008.md) | [(29.9)](/filings/0001720580-26-000037.md) | [(32.4)](/filings/0001720580-26-000050.md) | [(28.0)](/filings/0001193125-25-266880.md) | [(31.9) d](/filings/0001720580-26-000008.md) | [(21.6)](/filings/0001720580-26-000037.md) | [(22.3)](/filings/0001720580-26-000050.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-122253.md) | [0.0 d](/filings/0000950170-25-034587.md) | [0.0](/filings/0000950170-25-064448.md) | [0.0](/filings/0000950170-25-104978.md) | [0.0](/filings/0001193125-25-266880.md) | [0.0 d](/filings/0001720580-26-000008.md) | [0.0](/filings/0001720580-26-000037.md) | [0.0](/filings/0001720580-26-000050.md) | [0.0](/filings/0001193125-25-266880.md) | [0.0 d](/filings/0001720580-26-000008.md) | [0.0](/filings/0001720580-26-000037.md) | [0.0](/filings/0001720580-26-000050.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122253.md) | [0.0 d](/filings/0000950170-25-034587.md) | [0.0](/filings/0000950170-25-064448.md) | [0.0](/filings/0000950170-25-104978.md) | [0.0](/filings/0001193125-25-266880.md) | [0.0 d](/filings/0001720580-26-000008.md) | [0.0](/filings/0001720580-26-000037.md) | [0.0](/filings/0001720580-26-000050.md) | [0.0](/filings/0001193125-25-266880.md) | [0.0 d](/filings/0001720580-26-000008.md) | [0.0](/filings/0001720580-26-000037.md) | [0.1](/filings/0001720580-26-000050.md) |
| Net income | $m | [(49.9)](/filings/0000950170-24-122253.md) | [(29.5) d](/filings/0000950170-25-034587.md) | [(28.0)](/filings/0001193125-25-266880.md) | [(29.9)](/filings/0001193125-25-266880.md) | [(30.5)](/filings/0001193125-25-266880.md) | [(28.7) d](/filings/0001720580-26-000008.md) | [(28.2)](/filings/0001720580-26-000050.md) | [(31.2)](/filings/0001720580-26-000050.md) | [(26.9)](/filings/0001193125-25-266880.md) | [(30.5) d](/filings/0001720580-26-000008.md) | [(20.2)](/filings/0001720580-26-000050.md) | [(21.4)](/filings/0001720580-26-000050.md) |
| Diluted EPS | $ per share | [(1.16)](/filings/0000950170-24-122253.md) | not reported | [(0.35)](/filings/0000950170-25-064448.md) | [(0.33)](/filings/0000950170-25-104978.md) | [(0.34)](/filings/0001193125-25-266880.md) | not reported | [(4.96)](/filings/0001720580-26-000037.md) | [(5.48)](/filings/0001720580-26-000050.md) | [(0.29)](/filings/0001193125-25-266880.md) | not reported | [(1.88)](/filings/0001720580-26-000037.md) | [(1.99)](/filings/0001720580-26-000050.md) |
| Basic EPS | $ per share | [(1.16)](/filings/0000950170-24-122253.md) | not reported | [(0.35)](/filings/0000950170-25-064448.md) | [(0.33)](/filings/0000950170-25-104978.md) | [(0.34)](/filings/0001193125-25-266880.md) | not reported | [(4.96)](/filings/0001720580-26-000037.md) | [(5.48)](/filings/0001720580-26-000050.md) | [(0.29)](/filings/0001193125-25-266880.md) | not reported | [(1.88)](/filings/0001720580-26-000037.md) | [(1.99)](/filings/0001720580-26-000050.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [183](/filings/0000950170-23-061128.md) | [160](/filings/0000950170-25-034587.md) | [160](/filings/0000950170-25-064448.md) | [224](/filings/0000950170-25-104978.md) | [105](/filings/0001193125-25-266880.md) | [56.5](/filings/0001720580-26-000008.md) | [28.1](/filings/0001720580-26-000037.md) | [34.7](/filings/0001720580-26-000050.md) | [29.1](/filings/0001193125-25-266880.md) | [38.9](/filings/0001720580-26-000050.md) | [36.2](/filings/0001720580-26-000037.md) | [33.1](/filings/0001720580-26-000050.md) |
| Current assets | $m | [186](/filings/0000950170-23-061128.md) | [162](/filings/0000950170-25-034587.md) | [250](/filings/0000950170-24-059507.md) | [228](/filings/0000950170-24-095745.md) | [206](/filings/0000950170-24-122253.md) | [180](/filings/0001720580-26-000008.md) | [154](/filings/0000950170-25-064448.md) | [128](/filings/0000950170-25-104978.md) | [106](/filings/0001193125-25-266880.md) | [161](/filings/0001720580-26-000050.md) | [140](/filings/0001720580-26-000037.md) | [121](/filings/0001720580-26-000050.md) |
| Total assets | $m | [233](/filings/0000950170-23-061128.md) | [207](/filings/0000950170-25-034587.md) | [293](/filings/0000950170-24-059507.md) | [269](/filings/0000950170-24-095745.md) | [246](/filings/0000950170-24-122253.md) | [220](/filings/0001720580-26-000008.md) | [191](/filings/0000950170-25-064448.md) | [163](/filings/0000950170-25-104978.md) | [140](/filings/0001193125-25-266880.md) | [192](/filings/0001720580-26-000050.md) | [169](/filings/0001720580-26-000037.md) | [148](/filings/0001720580-26-000050.md) |
| Current liabilities | $m | [19.8](/filings/0000950170-23-061128.md) | [19.3](/filings/0000950170-25-034587.md) | [17.5](/filings/0000950170-24-059507.md) | [17.9](/filings/0000950170-24-095745.md) | [19.4](/filings/0000950170-24-122253.md) | [19.4](/filings/0001720580-26-000008.md) | [16.4](/filings/0000950170-25-064448.md) | [17.1](/filings/0000950170-25-104978.md) | [18.9](/filings/0001193125-25-266880.md) | [21.5](/filings/0001720580-26-000050.md) | [18.3](/filings/0001720580-26-000037.md) | [18.0](/filings/0001720580-26-000050.md) |
| Total liabilities | $m | [38.6](/filings/0000950170-23-061128.md) | [37.1](/filings/0000950170-25-034587.md) | [34.3](/filings/0000950170-24-059507.md) | [33.7](/filings/0000950170-24-095745.md) | [34.4](/filings/0000950170-24-122253.md) | [33.6](/filings/0001720580-26-000008.md) | [29.8](/filings/0000950170-25-064448.md) | [29.6](/filings/0000950170-25-104978.md) | [31.3](/filings/0001193125-25-266880.md) | [33.1](/filings/0001720580-26-000050.md) | [29.3](/filings/0001720580-26-000037.md) | [28.0](/filings/0001720580-26-000050.md) |
| Shareholders' equity | $m | [195](/filings/0000950170-24-122253.md) | [170](/filings/0001720580-26-000008.md) | [259](/filings/0001193125-25-266880.md) | [235](/filings/0001193125-25-266880.md) | [212](/filings/0001193125-25-266880.md) | [187](/filings/0001720580-26-000050.md) | [161](/filings/0001720580-26-000050.md) | [133](/filings/0001720580-26-000050.md) | [109](/filings/0001193125-25-266880.md) | [159](/filings/0001720580-26-000050.md) | [140](/filings/0001720580-26-000050.md) | [120](/filings/0001720580-26-000050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.2) d](/filings/0000950170-24-122253.md) | [(23.5) d](/filings/0000950170-25-034587.md) | [(22.8)](/filings/0000950170-25-064448.md) | [(23.4) d](/filings/0000950170-25-104978.md) | [(22.0) d](/filings/0001193125-25-266880.md) | [(24.1) d](/filings/0001720580-26-000008.md) | [(25.4)](/filings/0001720580-26-000037.md) | [(26.6) d](/filings/0001720580-26-000050.md) | [(22.3) d](/filings/0001193125-25-266880.md) | [(20.9) d](/filings/0001720580-26-000008.md) | [(21.5)](/filings/0001720580-26-000037.md) | [(19.8) d](/filings/0001720580-26-000050.md) |
| Capital expenditure | $m | [0.9 d](/filings/0000950170-24-122253.md) | [0.1 d](/filings/0000950170-25-034587.md) | [0.2](/filings/0000950170-25-064448.md) | [0.3 d](/filings/0000950170-25-104978.md) | [0.4 d](/filings/0001193125-25-266880.md) | [0.2 d](/filings/0001720580-26-000008.md) | [1.5](/filings/0001720580-26-000037.md) | [0.0 d](/filings/0001720580-26-000050.md) | [0.2 d](/filings/0001193125-25-266880.md) | [(0.0) d](/filings/0001720580-26-000008.md) | [0.0](/filings/0001720580-26-000037.md) | [0.2 d](/filings/0001720580-26-000050.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.6](/filings/0000950170-23-061128.md) | [43.0](/filings/0000950170-24-059507.md) | [43.0](/filings/0000950170-24-095745.md) | [43.0](/filings/0000950170-24-122253.md) | [79.1](/filings/0000950170-25-064448.md) | [90.6](/filings/0000950170-25-104978.md) | [90.8](/filings/0001193125-25-266880.md) | [5.7](/filings/0001720580-26-000037.md) | [5.7](/filings/0001720580-26-000050.md) | [91.1](/filings/0001193125-25-266880.md) | [10.7](/filings/0001720580-26-000037.md) | [10.7](/filings/0001720580-26-000050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,361,490 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001720580-26-000050.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.